IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
IGC Pharma (NYSE American:IGC) announced that Alliance Global Partners (AGP) has released an analyst update research report titled 'Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results.' The company explicitly states that analyst views represent those analysts only and not necessarily IGC Pharma's views. IGC emphasizes it is not responsible for the content, accuracy, or timelines provided by analysts, and referencing these analysts or distributing their opinions does not imply IGC's endorsement of the information, conclusions, or recommendations.
IGC Pharma (NYSE American:IGC) ha annunciato che Alliance Global Partners (AGP) ha pubblicato un rapporto di aggiornamento analitico intitolato 'Proseguendo gli sforzi per il targeting dell'Alzheimer con risultati intermedi notevoli della Fase 2 CALMA.' L'azienda dichiara esplicitamente che le opinioni degli analisti rappresentano solo quelle degli analisti stessi e non necessariamente le opinioni di IGC Pharma. IGC sottolinea di non essere responsabile per il contenuto, l'accuratezza o le tempistiche fornite dagli analisti, e il riferimento a questi analisti o la distribuzione delle loro opinioni non implica l'approvazione da parte di IGC delle informazioni, delle conclusioni o delle raccomandazioni.
IGC Pharma (NYSE American:IGC) anunció que Alliance Global Partners (AGP) ha publicado un informe de actualización analítica titulado 'Avanzando en los esfuerzos de targeting del Alzheimer con resultados intermedios notables de la Fase 2 CALMA.' La empresa declara explícitamente que las opiniones de los analistas representan solo a esos analistas y no necesariamente las opiniones de IGC Pharma. IGC enfatiza que no es responsable del contenido, la precisión o los plazos proporcionados por los analistas, y hacer referencia a estos analistas o distribuir sus opiniones no implica la aprobación de IGC sobre la información, las conclusiones o las recomendaciones.
IGC Pharma (NYSE American:IGC)는 Alliance Global Partners (AGP)가 '알츠하이머 타겟팅 노력을 진행하며 주목할 만한 2상 CALMA 중간 결과'라는 제목의 분석 업데이트 연구 보고서를 발표했다고 발표했습니다. 회사는 분석가의 견해가 해당 분석가의 것만을 나타내며 반드시 IGC Pharma의 견해를 반영하지는 않는다고 명시하고 있습니다. IGC는 분석가가 제공한 내용, 정확성 또는 일정에 대해 책임이 없으며, 이러한 분석가를 언급하거나 그들의 의견을 배포하는 것은 IGC가 정보, 결론 또는 권장 사항을 지지한다는 것을 의미하지 않음을 강조합니다.
IGC Pharma (NYSE American:IGC) a annoncé que Alliance Global Partners (AGP) a publié un rapport de recherche d'actualisation des analystes intitulé 'Progrès dans les efforts de ciblage de l'Alzheimer avec des résultats intermédiaires notables de la Phase 2 CALMA.' L'entreprise déclare explicitement que les opinions des analystes ne représentent que celles de ces analystes et ne reflètent pas nécessairement les opinions d'IGC Pharma. IGC souligne qu'elle n'est pas responsable du contenu, de l'exactitude ou des délais fournis par les analystes, et que la référence à ces analystes ou la distribution de leurs opinions n'implique pas l'approbation par IGC des informations, des conclusions ou des recommandations.
IGC Pharma (NYSE American:IGC) hat angekündigt, dass Alliance Global Partners (AGP) einen Analysten-Update-Forschungsbericht mit dem Titel 'Fortschritte bei den Alzheimer-Zielsetzungen mit bemerkenswerten Phase-2-CALMA-Zwischenergebnissen' veröffentlicht hat. Das Unternehmen erklärt ausdrücklich, dass die Ansichten der Analysten nur die der jeweiligen Analysten sind und nicht unbedingt die Ansichten von IGC Pharma widerspiegeln. IGC betont, dass es nicht verantwortlich ist für den Inhalt, die Genauigkeit oder die Zeitpläne, die von den Analysten bereitgestellt werden, und dass die Erwähnung dieser Analysten oder die Verbreitung ihrer Meinungen nicht die Billigung von IGC für die Informationen, Schlussfolgerungen oder Empfehlungen impliziert.
- Phase 2 CALMA trial is progressing with interim results notable enough to warrant analyst coverage
- Company provides no specific details about the actual trial results or progress
POTOMAC, MARYLAND / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.
A copy of the updated report can be obtained directly from Alliance Global Partners (AGP): LINK
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 32 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions. The Company operates a wellness brand offering scientifically formulated products under the brand Holiby™ and as white-labeled formulations.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key findings from IGC's Phase 2 CALMA trial interim results?
How is IGC's Alzheimer's treatment progressing in clinical trials?
What is the significance of AGP's analyst update for IGC stock?
When will IGC's Phase 2 CALMA trial complete?
